Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2026)

Acadia Pharmaceuticals' Cost of Revenue history runs 11 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 21.57% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $93.4 million (up 17.8% YoY), while the FY2025 annual figure was $89.0 million, up 8.75% from the prior year.
• Cost of Revenue was $24.8 million for Q1 2026 at Acadia Pharmaceuticals, down from $26.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $26.2 million in Q4 2025 to a low of $1.7 million in Q1 2023.
• Historically, Cost of Revenue has averaged $14.6 million across 5 years, with a median of $18.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue tumbled 77.54% in 2022, then surged 1276.78% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $2.4 million in 2022, then jumped by 641.44% to $17.9 million in 2023, then climbed by 21.87% to $21.8 million in 2024, then advanced by 20.28% to $26.2 million in 2025, then declined by 5.47% to $24.8 million in 2026.
• The last three Cost of Revenue figures came in at $24.8 million (Q1 2026), $26.2 million (Q4 2025), and $21.6 million (Q3 2025), per Business Quant data.